Dormicum en es it fr

Dormicum Brand names, Dormicum Analogs

Dormicum Brand Names Mixture

  • No information avaliable

Dormicum Chemical_Formula


Dormicum RX_link

Dormicum fda sheet

Dormicum msds (material safety sheet)

Dormicum MSDS

Dormicum Synthesis Reference

No information avaliable

Dormicum Molecular Weight

325.767 g/mol

Dormicum Melting Point

159 oC

Dormicum H2O Solubility

40.0 mg/ml

Dormicum State


Dormicum LogP


Dormicum Dosage Forms

Liquid; Solution

Dormicum Indication

For use in pediatric patients for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures or before induction of anesthesia.

Dormicum Pharmacology

Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.

Dormicum Absorption

Rapidly absorbed after oral administration (absolute bioavailability of the midazolam syrup in pediatric patients is about 36%, and intramuscular is greater than 90%).

Dormicum side effects and Toxicity

LD50=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.

Dormicum Patient Information

Dormicum Organisms Affected

Humans and other mammals